Literature DB >> 10398393

Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.

Z C Fan1, L Shan, B Z Goldsteen, L W Guddat, A Thakur, N F Landolfi, M S Co, M Vasquez, C Queen, P A Ramsland, A B Edmundson.   

Abstract

The objective of this work is to compare the three-dimensional structures of "humanized" and mouse-human chimeric forms of a murine monoclonal antibody elicited against human gamma-interferon. It is also to provide structural explanations for the small differences in the affinities and biological interactions of the two molecules for this antigen. Antigen-binding fragments (Fabs) were produced by papain hydrolysis of the antibodies and crystallized with polyethylene glycol (PEG) 8,000 by nearly identical microseeding procedures. Their structures were solved by X-ray analyses at 2.9 A resolution, using molecular replacement methods and crystallographic refinement. Comparison of these structures revealed marked similarities in the light (L) chains and near identities of the constant (C) domains of the heavy (H) chains. However, the variable (V) domains of the heavy chains exhibited substantial differences in the conformations of all three complementarity-determining regions (CDRs), and in their first framework segments (FR1). In FR1 of the humanized VH, the substitution of serine for proline in position 7 allowed the N-terminal segment (designated strand 4-1) to be closely juxtaposed to an adjacent strand (4-2) and form hydrogen bonds typical of an antiparallel beta-pleated sheet. The tightening of the humanized structure was relayed in such a way as to decrease the space available for the last portion of HFR1 and the first part of HCDR1. This compression led to the formation of an alpha-helix involving residues 25-32. With fewer steric constraints, the corresponding segment in the chimeric Fab lengthened by at least 1 A to a random coil which terminated in a single turn of 310 helix. In the humanized Fab, HCDR1, which is sandwiched between HCDR2 and HCDR3, significantly influenced the structures of both regions. HCDR2 was forced into a bent and twisted orientation different from that in the chimeric Fab, both at the crown of the loop (around proline H52a) and at its base. As in HCDR1, the last few residues of HCDR2 in the humanized Fab were compressed into a space-saving alpha-helix, contrasting with a more extended 310 helix in the chimeric form. HCDR3 in the humanized Fab was also adjusted in shape and topography. The observed similarities in the functional binding activities of the two molecules can be rationalized by limited induced fit adjustments in their structures on antigen binding. While not perfect replicas, the two structures are testimonials to the progress in making high affinity monoclonal antibodies safe for human use. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398393     DOI: 10.1002/(SICI)1099-1352(199901/02)12:1<19::AID-JMR445>3.0.CO;2-Y

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  9 in total

1.  Environmentally induced reversible conformational switching in the yeast cell adhesion protein alpha-agglutinin.

Authors:  H Zhao; M H Chen; Z M Shen; P C Kahn; P N Lipke
Journal:  Protein Sci       Date:  2001-06       Impact factor: 6.725

2.  Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetylglucosamine.

Authors:  Caroline Soliman; Anna K Walduck; Elizabeth Yuriev; Jack S Richards; Colette Cywes-Bentley; Gerald B Pier; Paul A Ramsland
Journal:  J Biol Chem       Date:  2018-02-15       Impact factor: 5.157

3.  A novel and conserved pocket of human kappa-Fab fragments: design, synthesis, and verification of directed affinity ligands.

Authors:  Enrique Carredano; Herbert Baumann; Anna Grönberg; Nils Norrman; Gunnar Glad; Jinyu Zou; Oguz Ersoy; Elles Steensma; Andreas Axén
Journal:  Protein Sci       Date:  2004-06       Impact factor: 6.725

4.  The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody.

Authors:  Caroline Soliman; Jia Xin Chua; Mireille Vankemmelbeke; Richard S McIntosh; Andrew J Guy; Ian Spendlove; Lindy G Durrant; Paul A Ramsland
Journal:  J Biol Chem       Date:  2019-12-12       Impact factor: 5.157

5.  Near-native protein loop sampling using nonparametric density estimation accommodating sparcity.

Authors:  Hyun Joo; Archana G Chavan; Ryan Day; Kristin P Lennox; Paul Sukhanov; David B Dahl; Marina Vannucci; Jerry Tsai
Journal:  PLoS Comput Biol       Date:  2011-10-20       Impact factor: 4.475

6.  Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.

Authors:  Sonia Covaceuszach; Sara Marinelli; Ivet Krastanova; Gabriele Ugolini; Flaminia Pavone; Doriano Lamba; Antonino Cattaneo
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

Review 7.  Early implementation of QbD in biopharmaceutical development: a practical example.

Authors:  Jesús Zurdo; Andreas Arnell; Olga Obrezanova; Noel Smith; Ramón Gómez de la Cuesta; Thomas R A Gallagher; Rebecca Michael; Yvette Stallwood; Caroline Ekblad; Lars Abrahmsén; Ingmarie Höidén-Guthenberg
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

8.  Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein.

Authors:  Constanze Breithaupt; Anna Schubart; Hilke Zander; Arne Skerra; Robert Huber; Christopher Linington; Uwe Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

9.  Aggregation risk prediction for antibodies and its application to biotherapeutic development.

Authors:  Olga Obrezanova; Andreas Arnell; Ramón Gómez de la Cuesta; Maud E Berthelot; Thomas R A Gallagher; Jesús Zurdo; Yvette Stallwood
Journal:  MAbs       Date:  2015       Impact factor: 5.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.